Conjunctival melanoma: Insights into classification, outcomes, and biomarkers

Shields, Carol L.; Silva, Ana Maria Velasco; Laiton, Andrea; Kalafatis, Nicholas E.; Schiller, Emily; Lally, Sara E.; Grant-Kels, Jane M.; Shields, Jerry A.

doi:10.1016/j.clindermatol.2023.10.010

Cited by 6 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can manifest as localized disease or spread on the eye surface, affecting the bulbar and palpebral conjunctiva extending over the limbus onto the cornea. Furthermore, it has the potential to infiltrate deeply into the sclera and other underlying structures of the globe as well as the orbital, nasolacrimal tissues, and paranasal sinuses [ 9 , 43 , 44 ].…”

Section: Introductionmentioning

confidence: 99%

Biological characteristics and clinical management of uveal and conjunctival melanoma

KAŠTELAN,

PAVIČIĆ,

PAŠALIĆ

et al. 2024

View full text Add to dashboard Cite

Uveal and conjunctival melanomas are relatively rare tumors; nonetheless, they pose a significant risk of mortality for a large number of affected individuals. The pathogenesis of melanoma at different sites is very similar, however, the prognosis for patients with ocular melanoma remains unfavourable, primarily due to its distinctive genetic profile and tumor microenvironment. Regardless of considerable advances in understanding the genetic characteristics and biological behaviour, the treatment of uveal and conjunctival melanoma remains a formidable challenge. To enhance the prospect of success, collaborative efforts involving medical professionals and researchers in the fields of ocular biology and oncology are essential. Current data show a lack of well-designed randomized clinical trials and limited benefits in current forms of treatment for these tumors. Despite advancements in the development of effective melanoma therapeutic strategies, all current treatments for uveal melanoma (UM) and conjunctival melanoma (CoM) remain unsatisfactory, resulting in a poor long-term prognosis. Ongoing trials offer hope for positive outcomes in advanced and metastatic tumors. A more comprehensive understanding of the genetic and molecular abnormalities involved in the development and progression of ocular melanomas opens the way for the development of personalized therapy, with various potential therapeutic targets currently under consideration. Increased comprehension of the molecular pathogenesis of UM and CoM and their specificities may aid in the development of new and more effective systemic therapeutic agents, with the hope of improving the prognosis for patients with metastatic disease.

show abstract

Section: Introductionmentioning

confidence: 99%